![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Amdocs Ltd | NASDAQ:DOX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.04 | 1.28% | 82.09 | 82.04 | 82.13 | 82.49 | 81.32 | 81.52 | 53,194 | 15:13:54 |
Expects Fiscal 2018 GAAP Diluted EPS Growth Outlook of 0.0%-6.0% YoY
“We are pleased to report solid results for our second fiscal quarter which included double-digit growth in Europe and record revenue in Rest of World. Our operating profitability was stable and we grew our 12-month backlog to another new high. Additionally, we extended our technology leadership with the launch of AmdocsOne at Mobile World Congress and we utilized our cash to close on the acquisitions of Vubiquity, as well as UXP Systems, a leader in User Lifecycle Management solutions,” said Eli Gelman, president and chief executive officer of Amdocs Management Limited.
Gelman continued, “Rest of World was a highlight of the quarter as we focused on project execution and securing new awards. In Southeast Asia, we commenced the ramp-up of the seven-year project and managed services agreement we signed with PLDT earlier in Q2. Additionally, we made an important step in Africa where we were selected to provide our revenue assurance capabilities to Safaricom, a major mobile network operator in Kenya with nearly 30 million subscribers.”
Gelman concluded, “We enter Q3 on-track to deliver a stronger second half, although we are of course monitoring the many moving parts affecting our outlook, including those resulting from consolidation activity currently in progress across our main operating regions. Additionally, we are focused on our execution and profitability, which combined with expected normalized free cash flow generation of approximately $500 million for the full year, leaves us well positioned to deliver diluted non-GAAP earnings per share growth in the range of 4% to 8% in fiscal 2018.”
Revenue
Net Income and Earnings Per Share
The Company's GAAP net income for the second quarter of fiscal 2018 was $101.7 million, or $0.70 per diluted share, compared to GAAP net income of $112.6 million, or $0.76 per diluted share, in the prior fiscal year’s second quarter. Net income on a non-GAAP basis was $137.4 million, or $0.95 per diluted share, compared to non-GAAP net income of $139.2 million, or $0.94 per diluted share, in the second quarter of fiscal 2017.
Returning Cash to Shareholders
Twelve-month BacklogTwelve-month backlog, which includes anticipated revenue related to contracts, estimated revenue from managed services contracts, letters of intent, maintenance and estimated on-going support activities, was $3.32 billion at the end of the second quarter of fiscal 2018, up $60 million from the end of the prior quarter.
Third Quarter Fiscal 2018 Outlook
Full Year Fiscal 2018 Outlook
Our third fiscal quarter 2018 and full year fiscal 2018 outlook takes into consideration the Company’s expectations regarding macro and industry specific risks and various uncertainties and certain assumptions that we will discuss on our earnings conference call. However, Amdocs notes market dynamics continue to shift rapidly and that it cannot predict all possible outcomes, including those resulting from AT&T’s proposed merger with Time Warner, T-Mobile’s proposed merger with Sprint, or from other current and potential customer consolidation activity in North America.
Conference Call Details Amdocs will host a conference call on May 10, 2018 at 5:00 p.m. Eastern Time to discuss the Company's second quarter of fiscal 2018 results. To participate, please dial +1 (844) 513-7152, or +1 (508) 637-5600 outside the United States, approximately 15 minutes before the call and enter passcode 4175387. The call will also be carried live on the Internet via the Amdocs website, www.amdocs.com. Non-GAAP Financial Measures This release includes non-GAAP diluted earnings per share and other non-GAAP financial measures, including free cash flow, non-GAAP cost of revenue, non-GAAP research and development, non-GAAP selling, general and administrative, non-GAAP operating income, non-GAAP operating margin, non-GAAP income taxes, non-GAAP effective tax rate, non-GAAP net income and non-GAAP diluted earnings per share growth. These non-GAAP measures exclude the following items:
These non-GAAP financial measures are not in accordance with, or an alternative for, generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies. In addition, these non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles. Amdocs believes that non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with Amdocs’ results of operations as determined in accordance with GAAP and that these measures should only be used to evaluate Amdocs’ results of operations in conjunction with the corresponding GAAP measures.
Amdocs believes that the presentation of non-GAAP diluted earnings per share and other financial measures, including free cash flow, non-GAAP cost of revenue, non-GAAP research and development, non-GAAP selling, general and administrative, non-GAAP operating income, non-GAAP operating margin, non-GAAP income taxes, non-GAAP effective tax rate, non-GAAP net income and non-GAAP diluted earnings per share growth when shown in conjunction with the corresponding GAAP measures, provides useful information to investors and management regarding financial and business trends relating to its financial condition and results of operations, as well as the net amount of cash generated by its business operations after taking into account capital spending required to maintain or expand the business.
For its internal budgeting process and in monitoring the results of the business, Amdocs’ management uses financial statements that do not include amortization of purchased intangible assets and other acquisition-related costs, changes in fair value of certain acquisition-related liabilities, equity-based compensation expense and related tax effects. Amdocs’ management also uses the foregoing non-GAAP financial measures, in addition to the corresponding GAAP measures, in reviewing the financial results of Amdocs. In addition, Amdocs believes that significant groups of investors exclude these items in reviewing its results and those of its competitors, because the amounts of the items between companies can vary greatly depending on the assumptions used by an individual company in determining the amounts of the items.
Amdocs further believes that, where the adjustments used in calculating non-GAAP diluted earnings per share are based on specific, identified amounts that impact different line items in the Consolidated Statements of Income (including cost of revenue, research and development, selling, general and administrative, operating income, income taxes and net income), it is useful to investors to understand how these specific line items in the Consolidated Statements of Income are affected by these adjustments. Please refer to the Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP tables below.
Supporting Resources
About AmdocsAmdocs is a leading software and services provider to the world’s most successful communications and media companies. As our customers reinvent themselves, we enable their digital and network transformation through innovative solutions, delivery expertise and intelligent operations. Amdocs and its 25,000 employees serve customers in over 85 countries. Listed on the NASDAQ Global Select Market, Amdocs had revenue of $3.9 billion in fiscal 2017.
For more information, visit Amdocs at www.amdocs.com.
This press release includes information that constitutes forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements about Amdocs’ growth and business results in future quarters. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations will not be material. Such statements involve risks and uncertainties that may cause future results to differ from those anticipated. These risks include, but are not limited to, the effects of general economic conditions, Amdocs’ ability to grow in the business markets that it serves, Amdocs’ ability to successfully integrate acquired businesses, adverse effects of market competition, rapid technological shifts that may render the Company's products and services obsolete, potential loss of a major customer, our ability to develop long-term relationships with our customers, and risks associated with operating businesses in the international market. Amdocs may elect to update these forward-looking statements at some point in the future; however, Amdocs specifically disclaims any obligation to do so. These and other risks are discussed at greater length in Amdocs’ filings with the Securities and Exchange Commission, including in our Annual Report on Form 20-F for the fiscal year ended September 30, 2017 filed on December 11, 2017 and our Form 6-K furnished for the first quarter of fiscal 2018 on February 12, 2018.
Contact: Matthew SmithHead of Investor RelationsAmdocs 314-212-8328 E-mail: dox_info@amdocs.com
AMDOCS LIMITED | ||||||||||||
Consolidated Statements of Income | ||||||||||||
(in thousands, except per share data) | ||||||||||||
Three months ended | Six months ended | |||||||||||
March 31, | March 31, | |||||||||||
2018 | 2017 | 2018 | 2017 | |||||||||
Revenue | $ | 992,340 | $ | 966,009 | $ | 1,970,051 | $ | 1,920,736 | ||||
Operating expenses: | ||||||||||||
Cost of revenue | 646,587 | 621,737 | 1,289,784 | 1,242,571 | ||||||||
Research and development | 64,926 | 67,303 | 133,103 | 127,293 | ||||||||
Selling, general and administrative | 120,199 | 114,465 | 238,867 | 238,544 | ||||||||
Amortization of purchased intangible assets and other | 28,801 | 28,723 | 54,327 | 56,954 | ||||||||
860,513 | 832,228 | 1,716,081 | 1,665,362 | |||||||||
Operating income | 131,827 | 133,781 | 253,970 | 255,374 | ||||||||
Interest and other expense, net | 239 | 468 | 118 | 3,231 | ||||||||
Income before income taxes | 131,588 | 133,313 | 253,852 | 252,143 | ||||||||
Income taxes | 29,861 | 20,753 | 35,252 | 41,790 | ||||||||
Net income | $ | 101,727 | $ | 112,560 | $ | 218,600 | $ | 210,353 | ||||
Basic earnings per share | $ | 0.71 | $ | 0.77 | $ | 1.52 | $ | 1.43 | ||||
Diluted earnings per share | $ | 0.70 | $ | 0.76 | $ | 1.51 | $ | 1.42 | ||||
Basic weighted average number of shares outstanding | 143,030 | 146,595 | 143,487 | 146,706 | ||||||||
Diluted weighted average number of shares outstanding | 144,390 | 147,954 | 144,882 | 148,168 | ||||||||
Cash dividends declared per share | $ | 0.250 | $ | 0.220 | $ | 0.470 | $ | 0.415 | ||||
AMDOCS LIMITED | ||||||||||||
Selected Financial Metrics | ||||||||||||
(in thousands, except per share data) | ||||||||||||
Three months ended | Six months ended | |||||||||||
March 31, | March 31, | |||||||||||
2018 | 2017 | 2018 | 2017 | |||||||||
Revenue | $ | 992,340 | $ | 966,009 | $ | 1,970,051 | $ | 1,920,736 | ||||
Non-GAAP operating income | 171,760 | 165,997 | 340,824 | 330,082 | ||||||||
Non-GAAP net income | 137,350 | 139,164 | 291,816 | 272,731 | ||||||||
Non-GAAP diluted earnings per share | $ | 0.95 | $ | 0.94 | $ | 2.01 | $ | 1.84 | ||||
Diluted weighted average number of shares outstanding | 144,390 | 147,954 | 144,882 | 148,168 | ||||||||
AMDOCS LIMITED | ||||||||||||||||
Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP | ||||||||||||||||
(in thousands) | ||||||||||||||||
Three months ended March 31, 2018 | ||||||||||||||||
Reconciliation items | ||||||||||||||||
GAAP | Amortization of purchased intangible assets and other | Equity based compensation expense | Changes in fair value of certain acquisition-related liabilities | Tax effect | Non-GAAP | |||||||||||
Operating expenses: | ||||||||||||||||
Cost of revenue | $ | 646,587 | $ | - | $ | (4,727 | ) | $ | (574 | ) | $ | - | $ | 641,286 | ||
Research and development | 64,926 | - | (769 | ) | - | - | 64,157 | |||||||||
Selling, general and administrative | 120,199 | - | (5,062 | ) | - | - | 115,137 | |||||||||
Amortization of purchased intangible assets and other | 28,801 | (28,801 | ) | - | - | - | - | |||||||||
Total operating expenses | 860,513 | (28,801 | ) | (10,558 | ) | (574 | ) | - | 820,580 | |||||||
Operating income | 131,827 | 28,801 | 10,558 | 574 | - | 171,760 | ||||||||||
Income taxes | 29,861 | - | - | - | 4,310 | 34,171 | ||||||||||
Net income | $ | 101,727 | $ | 28,801 | $ | 10,558 | $ | 574 | $ | (4,310 | ) | $ | 137,350 | |||
Three months ended March 31, 2017 | ||||||||||||||||
Reconciliation items | ||||||||||||||||
GAAP | Amortization of purchased intangible assets and other | Equity based compensation expense | Changes in fair value of certain acquisition-related liabilities | Tax effect | Non-GAAP | |||||||||||
Operating expenses: | ||||||||||||||||
Cost of revenue | $ | 621,737 | $ | - | $ | (4,973 | ) | $ | 6,691 | $ | - | $ | 623,455 | |||
Research and development | 67,303 | - | (901 | ) | - | - | 66,402 | |||||||||
Selling, general and administrative | 114,465 | - | (4,310 | ) | - | - | 110,155 | |||||||||
Amortization of purchased intangible assets and other | 28,723 | (28,723 | ) | - | - | - | - | |||||||||
Total operating expenses | 832,228 | (28,723 | ) | (10,184 | ) | 6,691 | - | 800,012 | ||||||||
Operating income | 133,781 | 28,723 | 10,184 | (6,691 | ) | - | 165,997 | |||||||||
Income taxes | 20,753 | - | - | - | 5,612 | 26,365 | ||||||||||
Net income | $ | 112,560 | $ | 28,723 | $ | 10,184 | $ | (6,691 | ) | $ | (5,612 | ) | $ | 139,164 | ||
AMDOCS LIMITED | |||||||||||||||||||
Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP | |||||||||||||||||||
(in thousands) | |||||||||||||||||||
Six months endedMarch 31, 2018 | |||||||||||||||||||
Reconciliation items | |||||||||||||||||||
GAAP | Amortization of purchased intangible assets and other | Equity based compensation expense | Changes in fair value of certain acquisition-related liabilities | Tax effect | One-time tax benefit relating to the new U.S. tax legislation | Non-GAAP | |||||||||||||
Operating expenses: | |||||||||||||||||||
Cost of revenue | $ | 1,289,784 | $ | - | $ | (9,425 | ) | $ | (8,464 | ) | $ | - | $ | - | $ | 1,271,895 | |||
Research and development | 133,103 | - | (1,593 | ) | - | - | 131,510 | ||||||||||||
Selling, general and administrative | 238,867 | - | (13,045 | ) | - | - | 225,822 | ||||||||||||
Amortization of purchased intangible assets and other | 54,327 | (54,327 | ) | - | - | - | - | ||||||||||||
Total operating expenses | 1,716,081 | (54,327 | ) | (24,063 | ) | (8,464 | ) | - | 1,629,227 | ||||||||||
Operating income | 253,970 | 54,327 | 24,063 | 8,464 | - | 340,824 | |||||||||||||
Income taxes | 35,252 | - | - | - | 10,688 | 2,950 | 48,890 | ||||||||||||
Net income | $ | 218,600 | $ | 54,327 | $ | 24,063 | $ | 8,464 | $ | (10,688 | ) | $ | (2,950 | ) | $ | 291,816 | |||
Six months ended March 31, 2017 | ||||||||||||||||
Reconciliation items | ||||||||||||||||
GAAP | Amortization of purchased intangible assets and other | Equity based compensation expense | Changes in fair value of certain acquisition-related liabilities | Tax effect | Non-GAAP | |||||||||||
Operating expenses: | ||||||||||||||||
Cost of revenue | $ | 1,242,571 | $ | - | $ | (9,971 | ) | $ | 6,691 | $ | - | $ | 1,239,291 | |||
Research and development | 127,293 | - | (1,800 | ) | - | - | 125,493 | |||||||||
Selling, general and administrative | 238,544 | - | (12,674 | ) | - | - | 225,870 | |||||||||
Amortization of purchased intangible assets and other | 56,954 | (56,954 | ) | - | - | - | - | |||||||||
Total operating expenses | 1,665,362 | (56,954 | ) | (24,445 | ) | 6,691 | - | 1,590,654 | ||||||||
Operating income | 255,374 | 56,954 | 24,445 | (6,691 | ) | - | 330,082 | |||||||||
Income taxes | 41,790 | - | - | - | 12,330 | 54,120 | ||||||||||
Net income | $ | 210,353 | $ | 56,954 | $ | 24,445 | $ | (6,691 | ) | $ | (12,330 | ) | $ | 272,731 | ||
AMDOCS LIMITED | ||||||
Condensed Consolidated Balance Sheets | ||||||
(in thousands) | ||||||
As of | ||||||
March 31, 2018 | September 30, 2017 | |||||
ASSETS | ||||||
Current assets | ||||||
Cash, cash equivalents and short-term interest-bearing investments | $ | 666,843 | $ | 979,608 | ||
Accounts receivable, net, including unbilled of $249,377 and $229,695, respectively | 972,279 | 865,068 | ||||
Prepaid expenses and other current assets | 221,825 | 203,810 | ||||
Total current assets | 1,860,947 | 2,048,486 | ||||
Property and equipment, net | 471,818 | 355,685 | ||||
Goodwill and other intangible assets, net | 2,780,956 | 2,398,535 | ||||
Other noncurrent assets | 465,270 | 476,674 | ||||
Total assets | $ | 5,578,991 | $ | 5,279,380 | ||
LIABILITIES AND EQUITY | ||||||
Current liabilities | ||||||
Accounts payable, accruals and other | $ | 1,141,799 | $ | 1,059,855 | ||
Short-term financing arrangements | 120,000 | - | ||||
Deferred revenue | 128,556 | 113,091 | ||||
Total current liabilities | 1,390,355 | 1,172,946 | ||||
Other noncurrent liabilities | 582,419 | 532,364 | ||||
Total Amdocs Limited Shareholders’ equity | 3,563,054 | 3,574,070 | ||||
Noncontrolling interests | 43,163 | - | ||||
Total equity | $ | 3,606,217 | $ | 3,574,070 | ||
Total liabilities and equity | $ | 5,578,991 | $ | 5,279,380 | ||
AMDOCS LIMITED | ||||||||
Consolidated Statements of Cash Flows | ||||||||
(in thousands) | ||||||||
Six months ended March 31, | ||||||||
2018 | 2017 | |||||||
Cash Flow from Operating Activities: | ||||||||
Net income | $ | 218,600 | $ | 210,353 | ||||
Reconciliation of net income to net cash provided by operating activities: | ||||||||
Depreciation and amortization | 102,900 | 109,038 | ||||||
Equity-based compensation expense | 24,063 | 24,445 | ||||||
Deferred income taxes | (3,584 | ) | 16,889 | |||||
Excess tax benefit from equity-based compensation | - | (2,929 | ) | |||||
loss (Gain) from short-term interest-bearing investments | 1,195 | (17 | ) | |||||
Net changes in operating assets and liabilities, net of amounts acquired: | ||||||||
Accounts receivable, net | (77,359 | ) | (25,092 | ) | ||||
Prepaid expenses and other current assets | (9,509 | ) | (10,926 | ) | ||||
Other noncurrent assets | (10,606 | ) | (42,294 | ) | ||||
Accounts payable, accrued expenses and accrued personnel | 23,103 | 25,101 | ||||||
Deferred revenue | 8,600 | (19,932 | ) | |||||
Income taxes payable, net | 8,675 | (8,813 | ) | |||||
Other noncurrent liabilities | (7,749 | ) | (469 | ) | ||||
Net cash provided by operating activities | 278,329 | 275,354 | ||||||
Cash Flow from Investing Activities: | ||||||||
Purchase of property and equipment | (162,126 | ) | (69,906 | ) | ||||
Proceeds from sale of short-term interest-bearing investments | 207,738 | 144,920 | ||||||
Purchase of short-term interest-bearing investments | (76,037 | ) | (145,737 | ) | ||||
Net cash paid for acquisitions | (352,599 | ) | - | |||||
Other | (3,446 | ) | 1,671 | |||||
Net cash used in investing activities | (386,470 | ) | (69,052 | ) | ||||
Cash Flow from Financing Activities: | ||||||||
Borrowings under financing arrangements | 120,000 | 200,000 | ||||||
Payments under financing arrangements | - | (200,000 | ) | |||||
Repurchase of shares | (239,779 | ) | (160,232 | ) | ||||
Investment by noncontrolling interest, net | 47,013 | - | ||||||
Proceeds from employee stock options exercised | 65,631 | 62,368 | ||||||
Payments of dividends | (63,294 | ) | (57,299 | ) | ||||
Excess tax benefit from equity-based compensation and other | (110 | ) | 2,929 | |||||
Net cash used in financing activities | (70,539 | ) | (152,234 | ) | ||||
Net (decrease) increase in cash and cash equivalents | (178,680 | ) | 54,068 | |||||
Cash and cash equivalents at beginning of period | 649,611 | 768,660 | ||||||
Cash and cash equivalents at end of period | $ | 470,931 | $ | 822,728 | ||||
AMDOCS LIMITED | |||||||||||||||
Supplementary Information | |||||||||||||||
(In millions) | |||||||||||||||
Three months ended | |||||||||||||||
March 31, 2018 | December 31, 2017 | September 30, 2017 | June 30, 2017 | March 31, 2017 | |||||||||||
North America | $ | 624.2 | $ | 643.0 | $ | 644.1 | $ | 637.9 | $ | 636.3 | |||||
Europe | 148.6 | 133.7 | 129.8 | 125.2 | 115.4 | ||||||||||
Rest of World | 219.5 | 201.0 | 205.8 | 203.6 | 214.3 | ||||||||||
Total Revenue | $ | 992.3 | $ | 977.7 | $ | 979.7 | $ | 966.7 | $ | 966.0 | |||||
Three months ended | |||||||||||||||
March 31, 2018 | December 31, 2017 | September 30, 2017 | June 30, 2017 | March 31, 2017 | |||||||||||
Managed Services Revenue | $ | 508.9 | $ | 518.7 | $ | 503.8 | $ | 496.3 | $ | 511.1 | |||||
Three months ended | |||||||||||||||
March 31, 2018 | December 31, 2017 | September 30, 2017 | June 30, 2017 | March 31, 2017 | |||||||||||
Customer Experience Solutions | $ | 980.7 | $ | 965.9 | $ | 967.7 | $ | 954.8 | $ | 948.6 | |||||
Directory | 11.6 | 11.8 | 12.0 | 11.9 | 17.4 | ||||||||||
Total Revenue | $ | 992.3 | $ | 977.7 | $ | 979.7 | $ | 966.7 | $ | 966.0 | |||||
As of | |||||||||||||||
March 31, 2018 | December 31, 2017 | September 30, 2017 | June 30, 2017 | March 31, 2017 | |||||||||||
12-Month Backlog | $ | 3,320 | $ | 3,260 | $ | 3,250 | $ | 3,220 | $ | 3,210 |
1 Year Amdocs Chart |
1 Month Amdocs Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions